GAFA
VRTX icon

Garton & Associates Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Garton & Associates Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-278
Closed -$126K – 687
2025
Q4 		$126K Buy
+278
New +$120K 0.07% 193

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Garton & Associates Financial Advisors's VRTX Position: Q1 2026 in Review

Garton & Associates Financial Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 278 shares — an estimated $126K sold.

Garton & Associates Financial Advisors first reported a position in VRTX in Q4 2025 and held it in 1 quarter. The position peaked at $126K in Q4 2025. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Garton & Associates Financial Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Garton & Associates Financial Advisors sold 278 Vertex Pharmaceuticals shares in Q1 2026, an estimated $126K.
  • Garton & Associates Financial Advisors first reported a position in Vertex Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Garton & Associates Financial Advisors's Vertex Pharmaceuticals position peaked at $126K in Q4 2025.
  • 1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Garton & Associates Financial Advisors's 13F filing for Q1 2026, filed 11 May 2026.